# SIRT1-Mediated Epigenetic Restoration of MFSD2A Expression Re-enables SPM Precursor Transport in Aged BBB
## Introduction and Background
The blood-brain barrier (BBB) represents a critical regulatory interface whose functional integrity deteriorates with physiological aging through mechanisms that remain incompletely characterized. Among the most consequential age-related changes at the BBB is the transcriptional silencing of **MFSD2A (Major Facilitator Superfamily Domain-containing 2A)**, a
Covalent conjugation of SPMs (RvD1, NPD1) to the sn-2 position of lysophosphatidylcholine creates MFSD2A-compatible prodrugs actively transported across CNS endothelium, where intracellular PLA2 releases the bioactive SPM moiety. This bypasses reliance on passive transcellular diffusion for polyhydroxylated, carboxylate-bearing SPMs.
Verdict Summary
3/10
dimensions won
SIRT1-Mediated Epigenetic Restoration of
7/10
dimensions won
MFSD2A-Targeted Lysophosphatidylcholine-
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.42
0.52
Evidence
0.50
0.68
Novelty
0.65
0.85
Feasibility
0.30
0.35
Impact
0.58
0.72
Druggability
0.55
0.45
Safety
0.70
0.55
Competition
0.75
0.70
Data
0.45
0.60
Reproducible
0.50
0.58
Score Breakdown
Dimension
SIRT1-Mediated Epigenetic Rest
MFSD2A-Targeted Lysophosphatid
Mechanistic
0.420
0.520
Evidence
0.500
0.680
Novelty
0.650
0.850
Feasibility
0.300
0.350
Impact
0.580
0.720
Druggability
0.550
0.450
Safety
0.700
0.550
Competition
0.750
0.700
Data
0.450
0.600
Reproducible
0.500
0.580
Evidence
SIRT1-Mediated Epigenetic Restoration of MFSD2A Expression R
Supporting Evidence
Age-dependent decrease in MFSD2A protein expression at brain microvasculature (12- and 24-month mice) is accompanied by PMID:36795730
MFSD2A suppresses caveolae-mediated transcytosis through lipid composition effects; loss of MFSD2A in aging simultaneousPMID:28416077
Circulating LPC-PUFA levels in older adults are inversely associated with cognitive decline risk, supporting LPC-MFSD2A PMID:32190891
ALOX15 (arachidonate 15-lipoxygenase) is the key biosynthetic enzyme producing resolvins and lipoxins from DHA/AA substrPMID:32806612
ABCA7, an AD risk gene involved in lipid efflux and phagocytosis, genetically co-operates with MFSD2A in maintaining memPMID:computational:ad_genetic_risk_loci
Contradicting Evidence
MFSD2A functions as multifunctional gatekeeper in brain and placenta - not exclusively regulated by SIRT1/KLF4, suggestiPMID:35710837
Global SIRT1 activation produces pleiotropic effects on neuronal metabolism, mitochondrial function, and immune cell behPMID:34135507
NMN and NR raise peripheral NAD+ more effectively than CNS NAD+; direct brain endothelial targeting is unprovenPMID:36795730
MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CN
Supporting Evidence
MFSD2A is exclusively expressed in BBB endothelium and transports DHA as LPC in a sodium-dependent mechanism; Mfsd2a-knoPMID:24828044
MFSD2A-transported lipids establish a unique endothelial lipid composition that suppresses caveolae vesicle formation, mPMID:28416077
Aging significantly reduces MFSD2A protein expression in brain microvascular endothelium, with 12- and 24-month-old micePMID:36795730
Circulating LPC is the preferred carrier of PUFAs across the BBB via MFSD2A; DHA supplementation in triglyceride form faPMID:32190891
SPMs including MaR1, RvD1, and NPD1 show compelling preclinical evidence for Alzheimer's disease neuroinflammation resolPMID:32806612
Contradicting Evidence
MFSD2A structure demonstrates a narrow, selective binding pocket incompatible with SPM-conjugated LPC derivatives - sn-1PMID:34135507